Coloplast A/S - Interim Financial Report, 9M 2024/25

Core Insights - Coloplast reported organic growth of 7% and an EBIT margin of 28% in Q3 2024/25, with reported revenue in DKK growing by 1% [1][4] - For the first nine months of 2024/25, organic growth remained at 7% with reported revenue increasing by 4% to DKK 20,914 million [2][4] - The company maintains its FY 2024/25 guidance for organic growth around 7% and an EBIT margin before special items of 27-28% [3][4] Financial Performance - EBIT for Q3 was DKK 1,915 million, a 2% increase from the previous year, with an EBIT margin of 28% compared to 27% last year [4] - Adjusted net profit before special items was DKK 3,778 million, a decrease of DKK 15 million from last year, with adjusted diluted EPS before special items decreasing by 1% to DKK 16.76 [4] - The reported growth in DKK is now expected to be 3-4%, with negative impacts from currency fluctuations and the Skin Care divestment [4] Business Segment Performance - Organic growth rates by business area include: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 4%, and Interventional Urology 4% [4] - Advanced Wound Care experienced a decline of -2% primarily due to a product return in China, expected to negatively impact revenue by around DKK 80 million in H2 [4] - Kerecis grew by 17% with a 13% EBIT margin before PPA amortization, although growth was impacted by a slowdown in the outpatient setting [4] Strategic Developments - Changes to the Executive Leadership Team were announced to support the execution of the new company strategy towards 2030 [4][5] - The search for Coloplast's new CEO is ongoing, with a presentation of the 2030 strategy planned for the Capital Markets Day on 2 September [5]